根治性膀胱切除术联合放化疗治疗肌层浸润性膀胱癌：治疗机构及社会人口统计学特征的影响
Radical Cystectomy Chemoradiation for Muscle-invasive Bladder Cancer: Impact of Treatment Facility and Sociodemographics.
作者信息
Haque Waqar, Verma Vivek, Butler E Brian, Teh Bin S
机构信息
Department of Radiation Oncology, CHI St Luke's Health, The Woodlands, TX, U.S.A.
Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, U.S.A.
出版信息
Anticancer Res. 2017 Oct;37(10):5603-5608. doi: 10.21873/anticanres.11994.
BACKGROUND
The present study sought to compare the differences in practice patterns, as well as clinical outcomes for patients with muscle-invasive bladder cancer undergoing treatment with either radical cystectomy (RC) or concurrent chemoradiaiton (CRT).
PATIENTS AND METHODS
The National Cancer Data Base (NCDB) was queried for patients diagnosed with T2/T3/T4aN0M0 bladder cancer, between 2004-2013, that received definitive treatment with either RC or CRT.
RESULTS
16,960 patients met the inclusion criteria; 1,450 (8.5%) underwent CRT, while 15,510 (91.5%) were treated with RC. Patients undergoing CRT were older, more likely to be female, African American, received treatment at an academic facility, and lived <20 miles of the treatment facility. CRT was associated with worse median OS (32.8 months vs. 36.1 months; p=0.0004).
CONCLUSION
Older patients are more likely to undergo bladder preservation therapy, while those living farther away from treatment facilities are less likely to under CRT.
背景
本研究旨在比较接受根治性膀胱切除术（RC）或同步放化疗（CRT）治疗的肌层浸润性膀胱癌患者的治疗模式差异以及临床结局。
患者与方法
查询国家癌症数据库（NCDB）中2004年至2013年间被诊断为T2/T3/T4aN0M0膀胱癌且接受了RC或CRT确定性治疗的患者。
结果
16960例患者符合纳入标准；1450例（8.5%）接受了CRT，而15510例（91.5%）接受了RC治疗。接受CRT的患者年龄更大，更可能为女性、非裔美国人，在学术机构接受治疗，且居住在距治疗机构<20英里的地方。CRT与更差的中位总生存期相关（32.8个月对36.1个月；p=0.0004）。
结论
老年患者更可能接受膀胱保留治疗，而居住在距治疗机构较远的患者接受CRT的可能性较小。
Zotero 插件